MGNX241018P3500
- 0.15
- 0.000.00%
Macrogenics Newsroom
Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
Express News | MacroGenics Shares Down 7.4% as Data Shows Worsening Safety Profile for Co's Prostate Cancer Drug
TD Cowen Maintains Macrogenics(MGNX.US) With Hold Rating
TD Cowen analyst Tara Bancroft maintains $Macrogenics(MGNX.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 56.1% and a total average return of 21.8% over the
Stifel Maintains Macrogenics(MGNX.US) With Hold Rating, Maintains Target Price $6
Stifel analyst Stephen Willey maintains $Macrogenics(MGNX.US)$ with a hold rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 43.6% and a
Evercore Maintains Macrogenics(MGNX.US) With Buy Rating
Evercore analyst Jonathan Miller maintains $Macrogenics(MGNX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 20.0% and a total average return of -22.6% over the
Evercore ISI Sticks to Their Buy Rating for MacroGenics (MGNX)
MacroGenics (MGNX) Receives a Hold From TD Cowen
Express News | MacroGenics Inc - Company Expects to Have Mature Median Rpfs No Later Than Early 2025
Do Options Traders Know Something About MacroGenics (MGNX) Stock We Don't?
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
HC Wainwright & Co. Reiterates Neutral on Macrogenics, Maintains $4 Price Target
H.C. Wainwright Maintains Macrogenics(MGNX.US) With Hold Rating, Maintains Target Price $4
H.C. Wainwright analyst Robert Burns maintains $Macrogenics(MGNX.US)$ with a hold rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 27.8% and
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Medtronic (MDT)
Citi Maintains Macrogenics(MGNX.US) With Buy Rating, Cuts Target Price to $14
Citi analyst Yigal Nochomovitz maintains $Macrogenics(MGNX.US)$ with a buy rating, and adjusts the target price from $16 to $14.According to TipRanks data, the analyst has a success rate of 43.6%
Macrogenics Is Maintained at Buy by Citigroup
Express News | MacroGenics Inc : Citigroup Cuts Target Price to $14 From $16
MacroGenics, Inc. (NASDAQ:MGNX) Just Reported, And Analysts Assigned A US$7.50 Price Target
MacroGenics, Inc. (NASDAQ:MGNX) Just Reported And Analysts Have Been Cutting Their Estimates
Buy Rating Affirmed for MacroGenics: Potential Growth Amid Oncology Trials and Solid Financials
MacroGenics (MGNX) Receives a Buy From Barclays